Login / Signup

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.

Christopher T RitchlinLaura C CoatesIain B McInnesPhillip J MeaseJoseph F MerolaYoshiya TanakaAkihiko AsahinaLaure GossecAlice B GottliebRichard B WarrenBarbara InkRajan BajracharyaVishvesh ShendeJason CoarseRobert B M Landewe
Published in: Annals of the rheumatic diseases (2023)
NCT03895203.
Keyphrases
  • placebo controlled
  • phase iii
  • double blind
  • open label
  • clinical trial
  • phase ii
  • study protocol
  • phase ii study
  • rheumatoid arthritis
  • randomized controlled trial
  • squamous cell carcinoma
  • replacement therapy